Related Experiment Video

Updated: May 10, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Hormonal regulation of Cyp4a isoforms in mouse liver and kidney

Youcai Zhang1, Curtis D Klaassen

  • 1Department of Internal Medicine, University of Kansas Medical Center , Kansas City, KS , USA.

Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|June 4, 2013
PubMed

Insights

Sex hormones and growth hormone (GH) dictate gender-specific expression of mouse Cyp4a genes in the liver and kidney. Androgens and male-pattern GH significantly influence these Cyp4a subfamily members, with distinct regulatory roles in different organs.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Genetics

Background:

  • The mouse Cyp4a subfamily exhibits distinct gender- and strain-specific expression patterns in the liver and kidney.
  • Specifically, Cyp4a12a and Cyp4a12b are male-predominant, while Cyp4a14 is female-predominant in C57BL/6 mice.
  • Cyp4a10 shows female predominance in the liver but no gender difference in the kidney.

Purpose of the Study:

  • To investigate the roles of sex hormones and growth hormone (GH) secretion patterns in the gender-specific expression of the Cyp4a subfamily in C57BL/6 mice.
  • To elucidate the specific contributions of androgens, estrogens, and GH to the regulation of Cyp4a isoforms in the liver and kidney.

Main Methods:

  • Utilized gonadectomized, GH-releasing hormone receptor-deficient (lit/lit), and hypophysectomized mouse models.
  • Administered sex hormones or GH to mimic male or female secretion patterns.
  • Analyzed Cyp4a mRNA expression in liver and kidney tissues.

Main Results:

  • In the liver, androgens and male-pattern GH co-regulated Cyp4a10, Cyp4a12a, and Cyp4a12b.
  • In the kidney, androgens exclusively regulated Cyp4a10 and Cyp4a12a, while male-pattern GH, not androgens, increased Cyp4a12b.
  • Female-predominant Cyp4a14 in both organs resulted from combined effects of male-pattern GH and androgens.
  • Estrogens had a minor, indirect regulatory role.

Conclusions:

  • Gender-divergent Cyp4a mRNA expression in the liver is primarily driven by male-pattern GH secretion and androgens.
  • In the kidney, Cyp4a mRNA expression is predominantly regulated by androgens.
  • These findings highlight the complex interplay of hormonal factors in tissue-specific gene regulation.

More Related Videos

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...